Bioactivity | L-Ascorbic acid (L-Ascorbate, Vitamin C), an electron donor, is an endogenous antioxidant agent. L-Ascorbic acid inhibits selectively Cav3.2 channels with an IC50 of 6.5 μM. L-Ascorbic acid is also a collagen deposition enhancer and an elastogenesis inhibitor[1][2][3]. L-Ascorbic acid exhibits anti-cancer effects through the generation of reactive oxygen species (ROS) and selective damage to cancer cells[4]. L-Ascorbic acid (GMP Like) is the GMP Like class L-Ascorbic acid (HY-B0166). |
Invitro | L-Ascorbic acid 的抗癌作用由钠依赖性维生素 C 转运蛋白 2 (SVCT-2) 决定,它是 L-Ascorbic acid 的转运蛋白。L-Ascorbic acid (0.1 μM-2 mM) 根据 SVCT-2 表达和 L-ascorbic acid 摄取表现出抗癌作用。人结直肠癌细胞系对 L-Ascorbic acid 表现出不同的反应,这主要取决于 SVCT-2 的表达水平[4]。 |
In Vivo | L-Ascorbic acid/Tolbutamide 在正常 (60 mg/kg) 和糖尿病 (40 mg/kg) 条件下以剂量依赖性方式产生降血糖活性。在 L-Ascorbic acid 存在的情况下,与 Tolbutamide 匹配对照相比,Tolbuatmide (20 mg/kg) 起效早且维持时间更长[5]。 |
Name | L-Ascorbic acid (GMP Like) |
CAS | 50-81-7 |
Formula | C6H8O6 |
Molar Mass | 176.12 |
Transport | Room temperature in continental US; may vary elsewhere. |
Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
Reference | [1]. Sebastian J Padayatty, et al. Vitamin C as an antioxidant: evaluation of its role in disease prevention. J Am Coll Nutr. 2003 Feb;22(1):18-35. [2]. Michael T Nelson, et al. Molecular mechanisms of subtype-specific inhibition of neuronal T-type calcium channels by ascorbate. J Neurosci. 2007 Nov 14;27(46):12577-83. [3]. Aleksander Hinek, et al. Sodium L-ascorbate enhances elastic fibers deposition by fibroblasts from normal and pathologic human skin. J Dermatol Sci. 2014 Sep;75(3):173-82. [4]. Sungrae Cho, et al. Hormetic dose response to L-ascorbic acid as an anti-cancer drug in colorectal cancer cell lines according to SVCT-2 expression. Sci Rep. 2018 Jul 27;8(1):11372. [5]. Satyanarayana Sreemantula, et al. Influence of antioxidant (L- ascorbic acid) on tolbutamide induced hypoglycaemia/antihyperglycaemia in normal and diabetic rats. BMC Endocr Disord. 2005 Mar 3;5(1):2. |